New Therapy for Metastatic Gastric and Gastroesophageal Cancers

Josep Tabernero, MD, PhD, ESMO president, director, Vall d’Hebron Institute of Oncology, Barcelona, Spain, summarizes the overall survival results from the TAGS study of trifluridine/tipiracil vs placebo in patients with metastatic gastric cancer refractory to standard therapies.